Immatics (IMTX) Competitors

Immatics has a net margin of -572.35% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Immatics' return on equity.

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CRISPR Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the broader market. Comparatively, Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Immatics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

In the previous week, CRISPR Therapeutics had 31 more articles in the media than Immatics. MarketBeat recorded 32 mentions for CRISPR Therapeutics and 1 mentions for Immatics. CRISPR Therapeutics' average media sentiment score of 0.50 beat Immatics' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

CRISPR Therapeutics presently has a consensus target price of $68.06, suggesting a potential upside of 27.16%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 115.54%. Given Immatics' stronger consensus rating and higher possible upside, analysts clearly believe Immatics is more favorable than CRISPR Therapeutics.

Immatics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Immatics' net margin of -572.35%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Immatics' return on equity.

ACADIA Pharmaceuticals has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Immatics presently has a consensus price target of $20.80, indicating a potential upside of 115.54%. ACADIA Pharmaceuticals has a consensus price target of $33.44, indicating a potential upside of 14.49%. Given Immatics' higher probable upside, research analysts plainly believe Immatics is more favorable than ACADIA Pharmaceuticals.

64.4% of Immatics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, ACADIA Pharmaceuticals had 32 more articles in the media than Immatics. MarketBeat recorded 33 mentions for ACADIA Pharmaceuticals and 1 mentions for Immatics. ACADIA Pharmaceuticals' average media sentiment score of 0.80 beat Immatics' score of 0.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Edgewise Therapeutics has higher earnings, but lower revenue than Immatics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

64.4% of Immatics shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Edgewise Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Edgewise Therapeutics' return on equity of -39.01% beat Immatics' return on equity.

Edgewise Therapeutics currently has a consensus price target of $48.75, suggesting a potential upside of 12.02%. Immatics has a consensus price target of $20.80, suggesting a potential upside of 115.54%. Given Immatics' higher probable upside, analysts clearly believe Immatics is more favorable than Edgewise Therapeutics.

Edgewise Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Immatics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market.

In the previous week, Edgewise Therapeutics had 17 more articles in the media than Immatics. MarketBeat recorded 18 mentions for Edgewise Therapeutics and 1 mentions for Immatics. Immatics' average media sentiment score of 0.00 beat Edgewise Therapeutics' score of -0.24 indicating that Immatics is being referred to more favorably in the news media.

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 5.3% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Viking Therapeutics currently has a consensus target price of $97.88, suggesting a potential upside of 185.68%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 115.54%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Viking Therapeutics is more favorable than Immatics.

Immatics has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Viking Therapeutics has a net margin of 0.00% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Viking Therapeutics' return on equity.

Viking Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

In the previous week, Viking Therapeutics had 9 more articles in the media than Immatics. MarketBeat recorded 10 mentions for Viking Therapeutics and 1 mentions for Immatics. Viking Therapeutics' average media sentiment score of 1.23 beat Immatics' score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.